Jae-Woo Jung1,2, Dong-Ki Kim3, Heung-Woo Park1,3, Kook-Hwan Oh3, Kwon-Wook Joo3, Yon-Su Kim3, Curie Ahn3, Kyung Wha Lee4, Sang-Heon Cho1,3, Kyung-Up Min1,3, Hye-Ryun Kang1,3. 1. Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea. 2. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. 3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 4. Hallym Institute for Genome Application, Hallym University College of Medicine, Anyang, Korea.
Abstract
PURPOSE: This study was conducted to evaluate the usefulness of human leukocyte antigen (HLA) typing in preventing allopurinol-induced severe cutaneous adverse reactions (SCARs) through the application of an allopurinol tolerance induction protocol or prescription of other alternative medications in high-risk patients. METHODS: HLA typing was performed in patients with chronic renal insufficiency who needed allopurinol. HLA-B*58:01-negative patients were prescribed the usual dose of allopurinol. For HLA-B*58:01-positive patients, administration of either allopurinol based on a 28-day tolerance induction protocol or alternative medications was initiated. Hypersensitivity reactions were surveyed for 90 days and compared with the result of a previous retrospective cohort study. RESULTS: Among a total of 401 study subjects, no SCARs were noted in HLA-B*58:01-positive patients with application of the tolerance induction protocol (n = 30) or alternative medications (n = 16), nor were any SCARs observed in HLA-B*58:01-negative patients who started allopurinol at the usual dose (n = 355). Compared with the previous retrospective cohort study, a significant reduction in SCARs was observed in HLA-B*58:01-positive patients (0 vs. 18%; P = 0.002). CONCLUSION: This study shows the usefulness of HLA-B*58:01 screening in identifying patients at high risk for the development of allopurinol-induced SCARs and suggests that application of a tolerance induction protocol or alternative medications could be an effective strategy to prevent allopurinol-induced SCARs in HLA-B*58:01-positive patients.
PURPOSE: This study was conducted to evaluate the usefulness of human leukocyte antigen (HLA) typing in preventing allopurinol-induced severe cutaneous adverse reactions (SCARs) through the application of an allopurinol tolerance induction protocol or prescription of other alternative medications in high-risk patients. METHODS: HLA typing was performed in patients with chronic renal insufficiency who needed allopurinol. HLA-B*58:01-negative patients were prescribed the usual dose of allopurinol. For HLA-B*58:01-positive patients, administration of either allopurinol based on a 28-day tolerance induction protocol or alternative medications was initiated. Hypersensitivity reactions were surveyed for 90 days and compared with the result of a previous retrospective cohort study. RESULTS: Among a total of 401 study subjects, no SCARs were noted in HLA-B*58:01-positive patients with application of the tolerance induction protocol (n = 30) or alternative medications (n = 16), nor were any SCARs observed in HLA-B*58:01-negative patients who started allopurinol at the usual dose (n = 355). Compared with the previous retrospective cohort study, a significant reduction in SCARs was observed in HLA-B*58:01-positive patients (0 vs. 18%; P = 0.002). CONCLUSION: This study shows the usefulness of HLA-B*58:01 screening in identifying patients at high risk for the development of allopurinol-induced SCARs and suggests that application of a tolerance induction protocol or alternative medications could be an effective strategy to prevent allopurinol-induced SCARs in HLA-B*58:01-positive patients.
Authors: Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Ursula Amstutz; Neil H Shear; Michael J Rieder; Soomi Hwang; Vincent Fung; Hidefumi Nakamura; Mary B Connolly; Shinya Ito; Bruce C Carleton Journal: Epilepsia Date: 2014-03-05 Impact factor: 5.864
Authors: Konstantina P Poulianiti; Antonia Kaltsatou; Georgia I Mitrou; Athanasios Z Jamurtas; Yiannis Koutedakis; Maria Maridaki; Ioannis Stefanidis; Giorgos K Sakkas; Christina Karatzaferi Journal: Oxid Med Cell Longev Date: 2016-08-03 Impact factor: 6.543